Gapping up
In reaction to earnings/guidance:
- ILMN +9.2% (guides Q1 and FY21 revs above consensus), SPNE +4.7% (guides Q1 and FY21 revs above consensus), LNN +1.7%, DCT +1.6%
Other news:
- SJ +38.2% (entered into a strategic alliance via a Master Services Agreement with Snipp Interactive)
- CARA +12.1% (to join S&P SmallCap 600)
- MUDS +7.3% (CNBC report that TOPPS will go public through a SPAC merger with MUDS)
- RMO +7.2% (Romeo Power and PACCAR (PCAR) enter long-term supply agreement for peterbilt 579 and 520 battery-electric vehicles)
- LABP +6.9% (receives FDA clearance for IND application for Omilancor)
- APTX +6.2% (recommences phase 2 study of NYX-458 in patients with cognitive impairment associated with parkinson's disease dementia and dementia with lewy bodies)
- TMDX +4.9% (shares halted as FDA is meeting today to review TransMedics' Organ Care System Heart System at 9 AM ET)
- MBRX +3.8% (engages IQVIA (IQV) to manage potential COVID-19 clinical trial)
- ROT +3.4% (Sarcos Robotics to merge with ROT)
- SEEL +3.3% (announces the signing of an agreement between Seelos and AptarGroup (ATR) for the co-exclusive use and supply of Aptar Pharma's Bidose Liquid System)
- BP +2.9% (reaches net debt target of $35 bln in Q1)
- DVAX +2.8% (Positive phase 1/2 results for Valneva's inactivated COVID-19 vaccine candidate using Dynavax's CpG 1018 adjuvant)
- SRRK +2.1% (announces positive 12-month top-line results from the TOPAZ Phase 2 clinical trial evaluating apitegromab in patients with type 2 and type 3 spinal muscular atrophy)
Analyst comments:
- SNAP +2.4% (upgraded to Overweight from Neutral at Atlantic Equities)
- VSH +2.1% (upgraded to Buy from Hold at Loop Capital)
- PARR +1.7% (upgraded to Buy from Neutral at Goldman)
- ALLE +1.6% (upgraded to Overweight from Underweight at Barclays)